Help us: Donate
Follow us on:

October 2019 MMTP Update


It has been a while since the last update from MMTP, so we wanted to let you know how things are progressing. 

As we explained in the last update, the internal review board (IRB) has concerns and further questions relating to the ethics of life extension and lifespan studies, and we are continuing to try to resolve these issues in order to be permitted to launch the study. The team has responded to the IRB, and the proposed lifespan study is under review once again.

Unfortunately, until the IRB responds, we cannot say if or when the lifespan study will be approved. This is disappointing news, and it also touches upon a wider issue in Europe, where, currently, high-quality lifespan studies are just not done in relation to life extension, and there is resistance to the idea.

This means it is more important than ever to continue fighting to get this study launched because if we do not keep pushing, no studies will ever be approved in the future, and Europe will not be part of lifespan studies supporting life extension. Therefore, this has become an important fight to change the system, and Dr. Stolzing is working hard to win this fight to open up lifespan studies in Europe that support the development of therapies that target aging.

That is the bad news, but there is also some good news too. While the team has been waiting, it has conducted some useful in vitro testing with a variety of senolytic compounds in various combinations. The team has already prepared the figures and methods and is currently preparing the experimental manuscript prior to submitting its findings for journal publication. The publication process can be time consuming, like many things in science, but the in vitro findings should prove interesting once published. 

We will keep you posted on developments as things change, and, hopefully soon, we will have some more positive news to report.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
  1. raphbot
    November 2, 2019

    Hello guys,

    At which point do you realize some regulations are just toxic and either ignore them or move on to more favorable countries?

    I may have missed it but was there a reason to choose and cling to a country so backward and rigid as Germany?

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.